2025/05/20 by Michael Davidson, Nadine Noël, Florent Schmitt +1 · 1 voice
Medicine · Biochemistry, Genetics and Molecular Biology · #Schizophrenia research and treatment #Treatment of Major Depression #Pharmacological Receptor Mechanisms and Effects
paper · pdf · doi:10.1093/ijnp/pyaf032
openalex publication_date 2025/05/20 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/30
Roluperidone is a drug in development targeting primary negative symptoms in schizophrenia, which binds sigma-2, 5-HT2A, and alpha1a receptors. Roluperidone administered as monotherapy to patients suffering from mild to moderate negative symptoms and withdrawal from antipsychotic drugs, improved negative symptoms in 2 clinical trials. The patients who were symptomatically stable for 3 or 6 months before antipsychotic drug withdrawal showed a very low rate of psychotic symptoms worsening over 6 or 9-month trial duration. Focus: Treatment of primary negative symptoms in a subgroup of patients suffering from schizophrenia.